Treatment principles in the management of autoimmune myasthenia gravis.

@article{Richman2003TreatmentPI,
  title={Treatment principles in the management of autoimmune myasthenia gravis.},
  author={David P. Richman and Mark A. Agius},
  journal={Annals of the New York Academy of Sciences},
  year={2003},
  volume={998},
  pages={457-72}
}
The pathogenesis of myasthenia gravis (MG) involves a T cell-directed antibody-mediated autoimmune attack on the nicotinic acetylcholine receptor (AChR) or, occasionally, on other postsynaptic antigens. The antibodies induce their effects through complement-mediated destruction of the postsynaptic endplate membrane with resultant reduction in endplate AChR… CONTINUE READING